Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Psychopharmacology
  4. Volume 12, Issue 1
  5. Article
Volume 12, Issue 1
  • ISSN: 2211-5560
  • E-ISSN: 2211-5579

Abstract

Tardive dyskinesia (TD) is induced by antipsychotic drugs that have dopamine-antagonising properties. It frequently causes physical and mental anguish in individuals, lowering their quality of life. Recent research on the aetiology and pathogenesis of TD indicates that genetic predisposition, treatment options, age, sex, and lifestyle factors are among the key risk factors contributing to the development of TD. Various genetic polymorphisms along with severe oxidative stress and other diseased conditions help to precipitate TD while on antipsychotic medications or other dopamine receptor blockers. Individuals diagnosed with schizophrenia are at a higher likelihood of developing TD. The current piece of literature aims to review the probable underlying mechanisms of TD, explore its pathophysiology, address the diagnostic challenges, and present the available treatment options. This comprehensive analysis draws from a range of published peer-reviewed publications, presenting the information in a clear and accessible manner.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpsp/10.2174/0122115560304943240822052622
2024-09-03
2025-06-23

  • From This Site

    /content/journals/cpsp/10.2174/0122115560304943240822052622
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SeigneurieA.S. SauvanaudF. LimosinF. Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs.Encephale201642324825410.1016/j.encep.2015.12.02126922134
     [Google Scholar]
  2. Arild Faurbye ClausenJ. FaurbyeA. Changes in serum proteins and cerebrospinal fluid proteins during pharmacotherapy of psychoses.Acta Psychiatr. Scand.196440110711610.1111/j.1600‑0447.1964.tb05737.x14211377
     [Google Scholar]
  3. FaurbyeA. RaschP-J. PetersenP.B. BrandborgG. PakkenbergH. Neurological symptoms in pharmagotherapy of psychoses.Acta Psychiatr. Scand.1964401102710.1111/j.1600‑0447.1964.tb05731.x14217630
     [Google Scholar]
  4. AryaD. KhanT. MargoliusA.J. FernandezH.H. Tardive dyskinesia: Treatment update.Curr. Neurol. Neurosci. Rep.20191996910.1007/s11910‑019‑0976‑131420757
     [Google Scholar]
  5. LernerV. MiodownikC. Motor symptoms of schizophrenia: Is tardive dyskinesia a symptom or side effect? A modern treatment.Curr. Psychiatry Rep.201113429530410.1007/s11920‑011‑0202‑621519907
     [Google Scholar]
  6. BashirH.H. JankovicJ. Treatment of tardive dyskinesia.Neurol. Clin.202038237939610.1016/j.ncl.2020.01.00432279716
     [Google Scholar]
  7. MillerR. ChouinardG. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia.Biol. Psychiatry1993341071373810.1016/0006‑3223(93)90044‑E7904833
     [Google Scholar]
  8. WoernerM.G. KaneJ.M. LiebermanJ.A. The prevalence of tardive dyskinesia.J. Clin. Psychopharmacol.1991111344210.1097/00004714‑199102000‑000051674949
     [Google Scholar]
  9. AbdetaT. TolessaD. TsegaW. Prevalence, and associated factors of tardive dyskinesia among psychiatric patients on first-generation antipsychotics at jimma university specialized hospital, psychiatric clinic, ethiopia: Institution based on a cross-sectional study.J Psychiatry Psychiatr Disord20193417919010.26502/jppd.2572‑519X0072
     [Google Scholar]
  10. CarbonM. HsiehC.H. KaneJ.M. CorrellC.U. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: A meta-analysis.J. Clin. Psychiatry2017783e264e27810.4088/JCP.16r1083228146614
     [Google Scholar]
  11. FaribaK.A. EstevezR. Tardive dystonia.StatPearls2023
     [Google Scholar]
  12. AdamsJD Tardive dyskinesia and dopamine oxidation, cumulative effects Multidiscip Sci J201922138141
     [Google Scholar]
  13. FreiK. Tardive dyskinesia: Who gets it and why.Parkinsonism Relat. Disord.20195915115410.1016/j.parkreldis.2018.11.01730522959
     [Google Scholar]
  14. WardK.M. CitromeL. Antipsychotic-related movement disorders: Drug-induced parkinsonism vs. Tardive dyskinesia—key differences in pathophysiology and clinical management.Neurol. Ther.20187223324810.1007/s40120‑018‑0105‑030027457
     [Google Scholar]
  15. CornettE.M. NovitchM. KayeA.D. KataV. KayeA.M. Medication-induced tardive dyskinesia: A review and update.Ochsner J.201717216217428638290
     [Google Scholar]
  16. MargoleseH.C. ChouinardG. KolivakisT.T. BeauclairL. MillerR. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: Pathophysiology and mechanisms of induction.Can. J. Psychiatry200550954154710.1177/07067437050500090716262110
     [Google Scholar]
  17. ThelmaB.K. SrivastavaV. TiwariA.K. Genetic underpinnings of tardive dyskinesia: Passing the baton to pharmacogenetics.Pharmacogenomics2008991285130610.2217/14622416.9.9.128518781856
     [Google Scholar]
  18. CaseyD.E. Tardive dyskinesia: Pathophysiology and animal models.J. Clin. Psychiatry200061Suppl. 45910739324
     [Google Scholar]
  19. GinovartN. WilsonA.A. HusseyD. HouleS. KapurS. D2-receptor upregulation is dependent upon temporal course of D2-occupancy: A longitudinal [11C]-raclopride PET study in cats.Neuropsychopharmacology200934366267110.1038/npp.2008.11618688210
     [Google Scholar]
  20. MahmoudiS. LévesqueD. BlanchetP.J. Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model.Mov. Disord.201429911251133
     [Google Scholar]
  21. SilvestriS. SeemanM.V. NegreteJ.C. Increased dopamine D 2 receptor binding after long-term treatment with antipsychotics in humans: A clinical PET study.Psychopharmacology2000152217418010.1007/s00213000053211057521
     [Google Scholar]
  22. C. Fibiger H. Neurobiological substrates of tardive dyskinesia: The GABA hypothesis.Trends Neurosci.198471246246410.1016/S0166‑2236(84)80254‑4
     [Google Scholar]
  23. CeladaP. PaladiniC.A. TepperJ.M. Gabaergic control of rat substantia nigra dopaminergic neurons: Role of globus pallidus and substantia nigra pars reticulata.Neuroscience199989381382510.1016/S0306‑4522(98)00356‑X10199615
     [Google Scholar]
  24. GudelskyG.A. MooreK.E. A comparison of the effects of haloperidol on dopamine turnover in the striatum, olfactory tubercule and median eminence.J. Pharmacol. Exp. Ther.19772021149156874811
     [Google Scholar]
  25. ElkashefA.M. WyattR.J. Tardive dyskinesia: Possible involvement of free radicals and treatment with vitamin E.Schizophr. Bull.199925473174010.1093/oxfordjournals.schbul.a03341410667743
     [Google Scholar]
  26. LohrJ.B. WyattR.J. CadetJ.L. Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms.Schizophr. Bull.198814229129610.1093/schbul/14.2.2912904696
     [Google Scholar]
  27. Juárez OlguínH. Calderón GuzmánD. Hernández GarcíaE. Barragán MejíaG. The role of dopamine and its dysfunction as a consequence of oxidative stress.Oxid. Med. Cell. Longev.2016201611310.1155/2016/973046726770661
     [Google Scholar]
  28. KonitsiotisS. TsironisC. KiortsisD.N. EvangelouA. Effects of N-methyl-d-aspartate receptor antagonism on neuroleptic-induced orofacial dyskinesias.Psychopharmacology2006185336937710.1007/s00213‑006‑0348‑916518645
     [Google Scholar]
  29. QuikM. BoydJ.T. BordiaT. PerezX. Potential therapeutic application for nicotinic receptor drugs in movement disorders.Nicotine Tob. Res.201921335736910.1093/ntr/nty06330137517
     [Google Scholar]
  30. TsaiH.T. CaroffS.N. MillerD.D. A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial.Am. J. Med. Genet. B. Neuropsychiatr. Genet.20082311719475583
     [Google Scholar]
  31. ZaiC.C. MaesM.S. TiwariA.K. ZaiG.C. RemingtonG. KennedyJ.L. Genetics of tardive dyskinesia: Promising leads and ways forward.J. Neurol. Sci.2018389283410.1016/j.jns.2018.02.01129502799
     [Google Scholar]
  32. LeeH.J. KangS.G. Genetics of tardive dyskinesia. In: International Review of Neurobiology.Elsevier Inc201123126410.1016/B978‑0‑12‑381328‑2.00010‑9
     [Google Scholar]
  33. MiksysS. WadjiF.B. TolledoE.C. RemingtonG. NobregaJ.N. TyndaleR.F. Rat brain CYP2D enzymatic metabolism alters acute and chronic haloperidol side-effects by different mechanisms.Prog. Neuropsychopharmacol. Biol. Psychiatry20177814014810.1016/j.pnpbp.2017.04.03028454738
     [Google Scholar]
  34. KapitanyT. MeszarosK. LenzingerE. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia.Schizophr. Res.199832210110610.1016/S0920‑9964(98)00038‑39713905
     [Google Scholar]
  35. JaansonP. MarandiT. KiivetR.A. Maintenance therapy with zuclopenthixol decanoate: Associations between plasma concentrations, neurological side effects and CYP2D6 genotype.Psychopharmacology20021621677310.1007/s00213‑002‑1059‑512107620
     [Google Scholar]
  36. TenbackD.E. van HartenP.N. Epidemiology and risk factors for (Tardive) dyskinesia. In: International Review of Neurobiology.Elsevier201198211230
     [Google Scholar]
  37. StilesL. ZhengY. DarlingtonC.L. SmithP.F. The D2 dopamine receptor and locomotor hyperactivity following bilateral vestibular deafferentation in the rat.Behav. Brain Res.2012227115015810.1016/j.bbr.2011.11.00622101174
     [Google Scholar]
  38. TurroneP. RemingtonG. KapurS. NobregaJ.N. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats.Psychopharmacology2003165216617110.1007/s00213‑002‑1259‑z12417967
     [Google Scholar]
  39. LatasterJ. van OsJ. de HaanL. Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: An experience sampling study.J. Clin. Psychiatry201172101397140410.4088/JCP.09m05466yel21208588
     [Google Scholar]
  40. ServonnetA. SamahaA.N. Antipsychotic-evoked dopamine supersensitivity.Neuropharmacology201913731077727
     [Google Scholar]
  41. D’souzaU. McguffinP. BucklandP.R. Antipsychotic regulation of dopamine D1, D2 and D3 receptor mRNA.Neuropharmacology19973611-121689169610.1016/S0028‑3908(97)00163‑99517440
     [Google Scholar]
  42. GumaE. RocchettiJ. DevenyiG.A. Role of D3 dopamine receptors in modulating neuroanatomical changes in response to antipsychotic administration.Sci. Rep.201991785010.1038/s41598‑019‑43955‑431127135
     [Google Scholar]
  43. LererB. SegmanR.H. FangerauH. Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism.Neuropsychopharmacology200227110511910.1016/S0893‑133X(02)00293‑212062911
     [Google Scholar]
  44. SrivastavaV. VarmaP.G. PrasadS. Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms.Pharmacogenet. Genomics200616211111710.1097/01.fpc.0000184957.98150.0f16424823
     [Google Scholar]
  45. RilstoneJ.J. AlkhaterR.A. MinassianB.A. Brain dopamine-serotonin vesicular transport disease and its treatment.N. Engl. J. Med.2013368654355010.1056/NEJMoa120728123363473
     [Google Scholar]
  46. MooslehnerK.A. ChanP.M. XuW. Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: Potential mouse model for parkinsonism.Mol. Cell. Biol.200121165321533110.1128/MCB.21.16.5321‑5331.200111463816
     [Google Scholar]
  47. LohrK.M. MillerG.W. VMAT2 and Parkinson’s disease: Harnessing the dopamine vesicle.Expert Rev. Neurother.201414101115111710.1586/14737175.2014.96039925220836
     [Google Scholar]
  48. ZaiC.C. TiwariA.K. MazzocoM. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia.J. Psychiatr. Res.201347111760176510.1016/j.jpsychires.2013.07.02524018103
     [Google Scholar]
  49. McMahonF.J. BuervenichS. CharneyD. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment.Am. J. Hum. Genet.200678580481410.1086/50382016642436
     [Google Scholar]
  50. NedergaardS. BolamJ.P. GreenfieldS.A. Facilitation of a dendritic calcium conductance by 5-hydroxytryptamine in the substantia nigra.Nature1988333616917417710.1038/333174a02897080
     [Google Scholar]
  51. MeltzerH.Y. An overview of the mechanism of action of clozapine.J. Clin. Psychiatry19944752
     [Google Scholar]
  52. Creed-CarsonM. OrahaA. NobregaJ.N. Effects of 5-HT2A and 5-HT2C receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats.Behav. Brain Res.2011219227327910.1016/j.bbr.2011.01.02521262266
     [Google Scholar]
  53. PozhidaevI.V. PaderinaD.Z. FedorenkoO.Y. 5-Hydroxytryptamine receptors and tardive dyskinesia in schizophrenia.Front. Mol. Neurosci.202013April6310.3389/fnmol.2020.0006332390801
     [Google Scholar]
  54. SegmanR.H. Heresco-LevyU. FinkelB. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia.Mol. Psychiatry20016222522910.1038/sj.mp.400084211317227
     [Google Scholar]
  55. BokeO. GunesS. KaraN. Association of serotonin 2A receptor and lack of association of CYP1A2 gene polymorphism with tardive dyskinesia in a Turkish population.DNA Cell Biol.200726852753110.1089/dna.2007.060517688403
     [Google Scholar]
  56. HerkenH. ErdalM.E. BökeÖ. SavaşH.A. Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol- o -methyltransferase gene ⋆.Eur. Psychiatry2003182778110.1016/S0924‑9338(03)00005‑112711403
     [Google Scholar]
  57. BasileV.S. OzdemirV. MasellisM. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia.Mol. Psychiatry20016223023410.1038/sj.mp.400084711317228
     [Google Scholar]
  58. TanE.C. ChongS.A. MahendranR. DongF. TanC.H. Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor.Biol. Psychiatry200150214414710.1016/S0006‑3223(01)01076‑911526996
     [Google Scholar]
  59. HsiehC.J. ChenY.C. LaiM.S. HongC.J. ChienK.L. Genetic variability in serotonin receptor and transporter genes may influence risk for tardive dyskinesia in chronic schizophrenia.Psychiatry Res.2011188117517610.1016/j.psychres.2010.10.00621055833
     [Google Scholar]
  60. TsermpiniE.E. RedenšekS. DolžanV. Genetic factors associated with tardive dyskinesia: From pre-clinical models to clinical studies.Front. Pharmacol.202212January83412910.3389/fphar.2021.83412935140610
     [Google Scholar]
  61. KoningJ.P. VehofJ. BurgerH. Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients.Psychopharmacology2012219372773610.1007/s00213‑011‑2394‑121750899
     [Google Scholar]
  62. SegmanR.H. Heresco-LevyU. FinkelB. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: Additive contribution of 5-HT2C ser and DRD3 gly alleles to susceptibility.Psychopharmacology2000152440841310.1007/s00213000052111140333
     [Google Scholar]
  63. Al HadithyA.F.Y. IvanovaS.A. PechlivanoglouP. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia.Prog. Neuropsychopharmacol. Biol. Psychiatry200933347548110.1016/j.pnpbp.2009.01.01019439249
     [Google Scholar]
  64. ZhangZ. ZhangX. HouG. ShaW. ReynoldsG.P. The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism.J. Psychiatr. Res.200236531732410.1016/S0022‑3956(02)00007‑912127599
     [Google Scholar]
  65. BakkerP.R. Al HadithyA.F.Y. AminN. van DuijnC.M. van OsJ. van HartenP.N. Antipsychotic-induced movement disorders in long-stay psychiatric patients and 45 tag SNPs in 7 candidate genes: A prospective study.PLoS One2012712e5097010.1371/journal.pone.005097023226551
     [Google Scholar]
  66. ZaiC.C. TiwariA.K. BasileV. Oxidative stress in tardive dyskinesia: Genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes.Prog. Neuropsychopharmacol. Biol. Psychiatry2010341505610.1016/j.pnpbp.2009.09.02019778569
     [Google Scholar]
  67. HoriH. OhmoriO. ShinkaiT. Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia.Neuropsychopharmacology200023217017710.1016/S0893‑133X(99)00156‑610882843
     [Google Scholar]
  68. HitzerothA. NiehausD.J.H. KoenL. BotesW.C. DeleuzeJ.F. WarnichL. Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population.Prog. Neuropsychopharmacol. Biol. Psychiatry200731366467210.1016/j.pnpbp.2006.12.01917291655
     [Google Scholar]
  69. GałeckiP. PietrasT. SzemrajJ. Manganese superoxide dismutase gene (MnSOD) polimorphism in schizophrenics with tardive dyskinesia from central PolandPsychiatr. Pol.200640593794817217237
     [Google Scholar]
  70. LiuH. WangC. ChenP.H. Association of the manganese superoxide dismutase gene Ala–9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients.Prog. Neuropsychopharmacol. Biol. Psychiatry201034469269610.1016/j.pnpbp.2010.03.02620346996
     [Google Scholar]
  71. GreenbaumL. AlkelaiA. ZozulinskyP. KohnY. LererB. Support for association of HSPG2 with tardive dyskinesia in Caucasian populations.Pharmacogenomics J.201212651352010.1038/tpj.2011.3221808285
     [Google Scholar]
  72. ZaiC.C. LeeF.H. TiwariA.K. Investigation of the HSPG2Gene in tardive dyskinesia-new data and meta-analysis.Front. Pharmacol.2018997410.3389/fphar.2018.0097430283332
     [Google Scholar]
  73. SyuA. IshiguroH. InadaT. Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia.Neuropsychopharmacology20103551155116410.1038/npp.2009.22020072119
     [Google Scholar]
  74. ChenC.H. WeiF.C. KoongF.J. HsiaoK.J. Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia.Biol. Psychiatry199741782782910.1016/S0006‑3223(96)00543‑49084902
     [Google Scholar]
  75. ZaiC.C. HwangR.W. De LucaV. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients.Int. J. Neuropsychopharmacol.200710563965110.1017/S146114570600715216959057
     [Google Scholar]
  76. HoriH. OhmoriO. ShinkaiT. KojimaH. NakamuraJ. Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia.Am. J. Med. Genet. B. Neuropsychiatr. Genet.2001105877477810.1002/ajmg.10045
     [Google Scholar]
  77. ZaiC.C. TiwariA.K. De LucaV. Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia.Eur. Neuropsychopharmacol.200919531732810.1016/j.euroneuro.2009.01.00119217756
     [Google Scholar]
  78. WoernerM.G. AlvirJ.M.J. SaltzB.L. LiebermanJ.A. KaneJ.M. Prospective study of tardive dyskinesia in the elderly: rates and risk factors.Am. J. Psychiatry1998155111521152810.1176/ajp.155.11.15219812112
     [Google Scholar]
  79. JesteD.V. CaligiuriM.P. PaulsenJ.S. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.Arch. Gen. Psychiatry199552975676510.1001/archpsyc.1995.039502100500107654127
     [Google Scholar]
  80. WoernerM.G. CorrellC.U. AlvirJ.M.J. GreenwaldB. DelmanH. KaneJ.M. Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: Results from a 2-year, prospective study in antipsychotic-naïve patients.Neuropsychopharmacology20113681738174610.1038/npp.2011.5521508932
     [Google Scholar]
  81. CorrellC.U. LeuchtS. KaneJ.M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies.Am. J. Psychiatry2004161341442510.1176/appi.ajp.161.3.41414992963
     [Google Scholar]
  82. CorrellC.U. SchenkE.M. Tardive dyskinesia and new antipsychotics.Curr. Opin. Psychiatry200821215115610.1097/YCO.0b013e3282f5313218332662
     [Google Scholar]
  83. YassaR. JesteD.V. Gender differences in tardive dyskinesia: A critical review of the literature.Schizophr. Bull.199218470171510.1093/schbul/18.4.7011359633
     [Google Scholar]
  84. TenbackD.E. van HartenP.N. van OsJ. Non‐therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: A meta‐analysis.Mov. Disord.200924162309231510.1002/mds.2270719645070
     [Google Scholar]
  85. MillerD.D. McEvoyJ.P. DavisS.M. Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial.Schizophr. Res.2005801334310.1016/j.schres.2005.07.03416171976
     [Google Scholar]
  86. CavallaroR. RegazzettiM.G. MundoE. BrancatoV. SmeraldiE. Tardive dyskinesia outcomes: Clinical and pharmacologic correlates of remission and persistence.Neuropsychopharmacology19938323323910.1038/npp.1993.268099483
     [Google Scholar]
  87. ThalitayaM.D. ReynoldsC. IsmailI. Study on the use of antipsychotic medication in an intellectual disability (ID) community caseload.Psychiatr. Danub.201729Suppl. 357858328953833
     [Google Scholar]
  88. MatsonJ.L. FodstadJ.C. NealD. DempseyT. RivetT.T. Risk factors for tardive dyskinesia in adults with intellectual disability, comorbid psychopathology, and long-term psychotropic use.Res. Dev. Disabil.201031110811610.1016/j.ridd.2009.08.00219720497
     [Google Scholar]
  89. van OsJ. FahyT. JonesP. HarveyI. TooneB. MurrayR. Tardive dyskinesia: Who is at risk?Acta Psychiatr. Scand.199796320621610.1111/j.1600‑0447.1997.tb10153.x9296552
     [Google Scholar]
  90. TelferS. ShivashankarS. KrishnadasR. McCreadieR.G. KirkpatrickB. Tardive dyskinesia and deficit schizophrenia.Acta Psychiatr. Scand.2011124535736210.1111/j.1600‑0447.2011.01751.x21838740
     [Google Scholar]
  91. RajanT.M. BharadwajB. RajkumarR.P. AdoleP.S. Frequency and correlates of tardive dyskinesia in Indian patients with type I bipolar disorder.Asian J. Psychiatr.20183232929810.1016/j.ajp.2017.12.00129222987
     [Google Scholar]
  92. KaneJ.M. WoernerM. LiebermanJ. Tardive dyskinesia.J. Clin. Psychopharmacol.198884Suppl.57S10.1097/00004714‑198808001‑000103065365
     [Google Scholar]
  93. BarnesT.R.E. LiddleP.F. CursonD.A. PatelM. Negative symptoms, tardive dyskinesia, and depression in chronic schizophrenia.Br. J. Psychiatry1989155S799103
     [Google Scholar]
  94. YassaR. NairV. SchwartzG. Tardive dyskinesia and the primary psychiatric diagnosis.Psychosomatics198425213513810.1016/S0033‑3182(84)73083‑06142494
     [Google Scholar]
  95. WuJ.Q. ChenD.C. XiuM.H. Tardive dyskinesia is associated with greater cognitive impairment in schizophrenia.Prog. Neuropsychopharmacol. Biol. Psychiatry201346717710.1016/j.pnpbp.2013.06.01323827756
     [Google Scholar]
  96. WolfM.E. RyanJ.J. MosnaimA.D. Cognitive functions in tardive dyskinesia.Psychol. Med.1983133671674
     [Google Scholar]
  97. VancampfortD. CorrellC.U. GallingB. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: A systematic review and large scale meta‐analysis.World Psychiatry201615216617410.1002/wps.2030927265707
     [Google Scholar]
  98. ShakhatrehM. JehangirA. MalikZ. ParkmanH.P. Metoclopramide for the treatment of diabetic gastroparesis.Expert Rev. Gastroenterol. Hepatol.201913871172110.1080/17474124.2019.164559431314613
     [Google Scholar]
  99. JacksonJ.G. DiazF.J. LopezL. de LeonJ. A combined analysis of worldwide studies demonstrates an association between bipolar disorder and tobacco smoking behaviors in adults.Bipolar Disord.201517657559710.1111/bdi.1231926238269
     [Google Scholar]
  100. KavanaghD.J. McGrathJ. SaundersJ.B. DoreG. ClarkD. Substance misuse in patients with schizophrenia: Epidemiology and management.Drugs200262574375510.2165/00003495‑200262050‑0000311929329
     [Google Scholar]
  101. HuntG.E. MalhiG.S. ClearyM. LaiH.M.X. SitharthanT. Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990–2015: Systematic review and meta-analysis.J. Affect. Disord.201620633134910.1016/j.jad.2016.07.01127476137
     [Google Scholar]
  102. ThomaP. DaumI. Comorbid substance use disorder in schizophrenia: A selective overview of neurobiological and cognitive underpinnings.Psychiatry Clin. Neurosci.201367636738310.1111/pcn.1207223890122
     [Google Scholar]
  103. CarbonM. KaneJ.M. LeuchtS. CorrellC.U. Tardive dyskinesia risk with first‐ and second‐generation antipsychotics in comparative randomized controlled trials: A meta‐analysis.World Psychiatry201817333034010.1002/wps.2057930192088
     [Google Scholar]
  104. SachdevP. Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: A prospective study.Aust. N. Z. J. Psychiatry200438644544910.1080/j.1440‑1614.2004.01382.x15209837
     [Google Scholar]
  105. KaneJ.M. KaneJ.M. Research diagnoses for tardive dyskinesia.Arch. Gen. Psychiatry198239448648710.1001/archpsyc.1982.042900400800146121550
     [Google Scholar]
  106. SchultzS.K. MillerD.D. ArndtS. ZiebellS. GuptaS. AndreasenN.C. Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation.Biol. Psychiatry1995381171371910.1016/0006‑3223(95)00082‑88580223
     [Google Scholar]
  107. MejiaN.I. JankovicJ. Tardive dyskinesia and withdrawal emergent syndrome in children.Expert Rev. Neurother.201010689390110.1586/ern.10.5820518606
     [Google Scholar]
  108. WalnO JankovicJ An update on tardive dyskinesia: From phenomenology to treatment.Tremor Other Hyperkinet Mov201330310.5334/tohm.16523858394
     [Google Scholar]
  109. MorgensternH. GlazerW.M. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.Arch. Gen. Psychiatry199350972373310.1001/archpsyc.1993.018202100570078102845
     [Google Scholar]
  110. van HartenP.N. HoekH.W. MatroosG.E. KoeterM. KahnR.S. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao extrapyramidal syndromes study III.Am. J. Psychiatry1998155456556710.1176/ajp.155.4.5659546009
     [Google Scholar]
  111. KlawansH.L. RubovitsR. Effect of cholinergic and anticholinergic agents on tardive dyskinesia.J. Neurol. Neurosurg. Psychiatry197437894194710.1136/jnnp.37.8.9414418481
     [Google Scholar]
  112. DesmaraisJ.E. BeauclairL. MargoleseH.C. Anticholinergics in the era of atypical antipsychotics: Short-term or long-term treatment?J. Psychopharmacol.20122691167117410.1177/026988111244798822651987
     [Google Scholar]
  113. Soares-WeiserK MobsyC HollidayE Anticholinergic medication for neuroleptic-induced tardive dyskinesia.Cochrane Database Syst Rev1997210.1002/14651858.CD000204
     [Google Scholar]
  114. GranacherR.P.Jr GranacherJ.R. Differential diagnosis of tardive dyskinesia: An overview.Am. J. Psychiatry1981138101288129710.1176/ajp.138.10.12886457534
     [Google Scholar]
  115. JainR. CorrellC.U. Tardive dyskinesia: Recognition, patient assessment, and differential diagnosis.J. Clin. Psychiatry2018792162310.4088/JCP.nu17034ah1c29570969
     [Google Scholar]
  116. MattinglyG. MattinglyG.W. Diagnostic dilemmas in patients with tardive dyskinesia.Curr. Psychiatr.2022201158
     [Google Scholar]
  117. ChouinardG. MargoleseH.C. Manual for the extrapyramidal symptom rating scale (ESRS).Schizophr. Res.2005762-324726510.1016/j.schres.2005.02.01315949657
     [Google Scholar]
  118. SimpsonG.M. LeeJ.H. ZoubokB. GardosG. A rating scale for tardive dyskinesia.Psychopharmacology197964217117910.1007/BF00496058115037
     [Google Scholar]
  119. GoodwinF.K. From the alcohol, drug abuse, and mental health administration.JAMA199026411138910.1001/jama.1990.034501100350062167987
     [Google Scholar]
  120. GardosG. ColeJ.O. La BrieR. The assessment of tardive dyskinesia.Arch. Gen. Psychiatry197734101206121210.1001/archpsyc.1977.01770220088010911220
     [Google Scholar]
  121. TryonW.W. PologeB. Accelerometric assessment of tardive dyskinesia.Am. J. Psychiatry1987144121584158710.1176/ajp.144.12.15842891307
     [Google Scholar]
  122. WuQ YuanF ZhangS LiuW MiaoQ ZhengX Correlation of blood biochemical markers with tardive dyskinesia in schizophrenic patients.Dis Markers2022202210.1155/2022/1767989
     [Google Scholar]
  123. UludagK WangDM ZhangXY Tardive dyskinesia development, superoxide dismutase levels, and relevant genetic polymorphisms.Oxid Med Cell Longev2022202210.1155/2022/5748924
     [Google Scholar]
  124. GilbertP.L. HarrisM.J. McAdamsL.A. JesteD.V. Neuroleptic withdrawal in schizophrenic patients. A review of the literature.Arch. Gen. Psychiatry199552317318810.1001/archpsyc.1995.039501500050017872841
     [Google Scholar]
  125. RicciardiL. PringsheimT. BarnesT.R.E. Treatment recommendations for tardive dyskinesia.Can. J. Psychiatry201964638839910.1177/070674371982896830791698
     [Google Scholar]
  126. MeyerJ.M. Forgotten but not gone: New developments in the understanding and treatment of tardive dyskinesia.CNS Spectr.201621S1132410.1017/S1092852916000730
     [Google Scholar]
  127. GlazerW.M. MorgensternH. SchoolerN. BerkmanC.S. MooreD.C. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication.Br. J. Psychiatry19901574585592
     [Google Scholar]
  128. FrangosE. ChristodoulidesH. Clinical observations of the treatment of tardive dyskinesia with haloperidol.Acta Psychiatr. Belg.19757511932785948
     [Google Scholar]
  129. KazamatsuriH. ChienC. ColeJ.O. Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate.Arch. Gen. Psychiatry197227110010310.1001/archpsyc.1972.017502500860124555826
     [Google Scholar]
  130. BernsteinA.I. StoutK.A. MillerG.W. The vesicular monoamine transporter 2: An underexplored pharmacological target.Neurochem. Int.201473899710.1016/j.neuint.2013.12.00324398404
     [Google Scholar]
  131. O’BrienC.F. JimenezR. HauserR.A. NBI‐98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study.Mov. Disord.201530121681168710.1002/mds.2633026346941
     [Google Scholar]
  132. HauserR.A. FactorS.A. MarderS.R. KINECT 3: A phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia.Am. J. Psychiatry2017174547648410.1176/appi.ajp.2017.1609103728320223
     [Google Scholar]
  133. LillianL. SmithM. JuanF. MosleyI. JessicaR.F. TiffaniR. Vesicular monoamine transporter type 2 (VMAT2) inhibitors in the management of tardive dyskinesia.Clin. Med. Rev. Case Rep.201741215
     [Google Scholar]
  134. CaroffS.N. Risk of neuroleptic malignant syndrome with vesicular monoamine transporter inhibitors.Clin. Psychopharmacol. Neurosci.202018232232610.9758/cpn.2020.18.2.32232329312
     [Google Scholar]
  135. VijayakumarD. JankovicJ. Drug-induced dyskinesia, part 2: Treatment of tardive dyskinesia.Drugs201676777978710.1007/s40265‑016‑0568‑127091214
     [Google Scholar]
  136. OndoW.G. HannaP.A. JankovicJ. Tetrabenazine treatment for tardive dyskinesia: Assessment by randomized videotape protocol.Am. J. Psychiatry199915681279128110.1176/ajp.156.8.127910450276
     [Google Scholar]
  137. BobruffA. GardosG. TarsyD. RapkinR.M. ColeJ.O. MooreP. Clonazepam and phenobarbital in tardive dyskinesia.Am. J. Psychiatry1981138218919310.1176/ajp.138.2.1896109454
     [Google Scholar]
  138. ThakerG.K. NguyenJ.A. StraussM.E. JacobsonR. KaupB.A. TammingaC.A. Clonazepam treatment of tardive dyskinesia: A practical GABAmimetic strategy.Am. J. Psychiatry1990147444545110.1176/ajp.147.4.4451969244
     [Google Scholar]
  139. PappaS. TsouliS. ApostolouG. MavreasV. KonitsiotisS. Effects of amantadine on tardive dyskinesia: A randomized, double-blind, placebo-controlled study.Clin. Neuropharmacol.201033627127510.1097/WNF.0b013e3181ffde3221121175
     [Google Scholar]
  140. ShamirE. BarakY. ShalmanI. Melatonin treatment for tardive dyskinesia: A double-blind, placebo-controlled, crossover study.Arch. Gen. Psychiatry200158111049105210.1001/archpsyc.58.11.104911695951
     [Google Scholar]
  141. SpindlerM.A. GalifianakisN.B. WilkinsonJ.R. DudaJ.E. Globus pallidus interna deep brain stimulation for tardive dyskinesia: Case report and review of the literature.Parkinsonism Relat. Disord.201319214114710.1016/j.parkreldis.2012.09.01623099106
     [Google Scholar]
  142. BhidayasiriR. FahnS. WeinerW.J. GronsethG.S. SullivanK.L. ZesiewiczT.A. Evidence-based guideline: Treatment of tardive syndromes.Neurology2013815463469
     [Google Scholar]
  143. Soares-WeiserK RathboneJ. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.Cochrane Database Syst Rev20061
     [Google Scholar]
  144. BaiY.M. YuS.C. LinC.C. Risperidone for severe tardive dyskinesia: A 12-week randomized, double-blind, placebo-controlled study.J. Clin. Psychiatry200364111342134810.4088/JCP.v64n111014658949
     [Google Scholar]
  145. BoomershineK.H. SheltonP.S. BoomershineJ.E. Vitamin E in the treatment of tardive dyskinesia.Ann. Pharmacother.199933111195120210.1345/aph.1702510573320
     [Google Scholar]
  146. ElkashefA.M. RuskinP.E. BacherN. BarrettD. Vitamin E in the treatment of tardive dyskinesia.Am. J. Psychiatry1990147450550610.1176/ajp.147.4.5051969247
     [Google Scholar]
  147. ZhangW.F. TanY.L. ZhangX.Y. ChanR.C.K. WuH.R. ZhouD.F. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: A randomized, double-blind, placebo-controlled trial.J. Clin. Psychiatry201172561562110.4088/JCP.09m05125yel20868638
     [Google Scholar]
  148. SlotemaC.W. van HartenP.N. BruggemanR. HoekH.W. Botulinum toxin in the treatment of orofacial tardive dyskinesia: A single blind study.Prog. Neuropsychopharmacol. Biol. Psychiatry200832250750910.1016/j.pnpbp.2007.10.00418022743
     [Google Scholar]
  149. JankovicJ. Treatment of hyperkinetic movement disorders with tetrabenazine: A double‐blind crossover study.Ann. Neurol.1982111414710.1002/ana.4101101086460467
     [Google Scholar]
  150. FernandezH.H. FactorS.A. HauserR.A. Randomized controlled trial of deutetrabenazine for tardive dyskinesia.Neurology201788212003201010.1212/WNL.000000000000396028446646
     [Google Scholar]
/content/journals/cpsp/10.2174/0122115560304943240822052622
Loading
A Literature-Based Study of Tardive Dyskinesia- From Pathogenesis to Treatment
Current Psychopharmacology 12, E22115560304943 (2024); https://doi.org/10.2174/0122115560304943240822052622
/content/journals/cpsp/10.2174/0122115560304943240822052622
/content/journals/cpsp/10.2174/0122115560304943240822052622
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): dopamine blockers; dyskinesia; haloperidol; movement disorder; Tardive dyskinesia; VMAT-2

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test